Several studies suggested Lgr5+ as resistant not only to 5-FU but also to other components of commonly used CRC chemotherapy regimens such as Oxaliplatin and Irinotecan (Kobayashi et al. 2012; Zhang et al. 2019). The gene discussed is LGR5; the disease is colorectal carcinoma.